Provided by Tiger Trade Technology Pte. Ltd.

Incyte

120.10
-1.2500-1.03%
Volume:312.72K
Turnover:37.59M
Market Cap:24.34B
PE:15.30
High:121.22
Open:121.05
Low:119.42
Close:121.35
52wk High:132.60
52wk Low:82.82
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.42
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.84
PE(LYR):18.74

Loading ...

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS
·
Jul 28

Corrected-Incyte Q2 Revenue USD 1,674 Million VS. Ibes Estimate USD 1,474 Million (Corrects Amount)

THOMSON REUTERS
·
Jul 28

Incyte Corp. Stock Underperforms Monday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 28

Cintas, KeyCorp, Butterfly Network, Conagra, Incyte Insider Shake-Up

TIPRANKS
·
Jul 25

Incyte is Maintained at Equal-weight by Morgan Stanley

Dow Jones
·
Jul 24

Incyte Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Jul 23

Morgan Stanley Adjusts Price Target on Incyte to $104 From $103, Maintains Equalweight Rating

MT Newswires Live
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), Immunome (IMNM) and Incyte (INCY)

TIPRANKS
·
Jul 22

Incyte: ENHANZE Licensing Bolsters INCA033989 Outlook as Buy Rating and $140 Price Target Are Reiterated

TIPRANKS
·
Jul 22

Incyte Price Target Maintained with a $140.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 21

Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued

Simply Wall St.
·
Jul 21

Earning Preview: Incyte Q2 revenue is expected to increase by 24.52%, and institutional views are bullish

Earnings Agent
·
Jul 21

Top Incyte Executives Quietly Lock In Profits With Fresh Stock Sales

TIPRANKS
·
Jul 21

Incyte Corp. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jul 21

Incyte EVP, Head of U.S. Commercial Issa Mohamed Khairie Sells 1,093 Shares for $125,705.93

Reuters
·
Jul 21

Halozyme Therapeutics, Incyte Sign Deal to Develop Subcutaneous Formulations of Blood Cancer Drug

MT Newswires Live
·
Jul 20

Goldman Sachs Adjusts Price Target on Incyte to $110 From $100, Maintains Neutral Rating

MT Newswires Live
·
Jul 20

Halozyme announces global collaboration, license agreement with Incyte

TIPRANKS
·
Jul 20

Halozyme Partners with Incyte on Enhanze Subcutaneous Formulation for Inca033989 Antibody

Reuters
·
Jul 20

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of Inca033989 Using Its Enhanze® Technology

THOMSON REUTERS
·
Jul 20